• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Silence Therapeutics Plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    5/18/26 5:00:15 PM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLN alert in real time by email
    8-K
    true0001479615false00-00000000001479615dei:AdrMember2026-05-182026-05-1800014796152026-05-182026-05-180001479615us-gaap:CommonStockMember2026-05-182026-05-18

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 18, 2026

    Silence Therapeutics plc

    (Exact name of Registrant as Specified in Its Charter)

    England and Wales

    001-39487

    Not Applicable

    (State or Other Jurisdiction

    of Incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

    12 Hammersmith Grove

    London

    United Kingdom

    W6 7AP

    (Address of Principal Executive Offices)

    (Zip Code)

    Registrant’s Telephone Number, Including Area Code: +44 20 3457 6900

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading

    Symbol(s)

    Name of each exchange on which registered

    American Depositary Shares, each representing three ordinary shares, nominal value £0.05 per share

    SLN

    The Nasdaq Stock Market LLC

    Ordinary share, nominal value £0.05 per share*

    *

    The Nasdaq Stock Market LLC

    * Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     


     

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 1.01 Entry into a Material Definitive Agreement.

    On May 18, 2026, Silence Therapeutics plc (the “Company” or “we”) entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Jefferies as its sales agent and/or principal, American Depositary Shares of the Company (the “ADSs”), each representing three ordinary shares, nominal value £0.05 per share of the Company, having an aggregate offering amount not exceeding the Maximum Program Amount, as such term is defined in the Sales Agreement. The Sales Agreement replaces the prior Open Market Sale AgreementSM, dated October 15, 2021, by and between the Company and Jefferies (the “Prior Sales Agreement’), which was terminated as of May 18, 2026 pursuant to the terms of the Sales Agreement.

    The Company is not obligated to sell any ADSs under the Sales Agreement. Upon delivery of an issuance notice and subject to the terms and conditions of the Sales Agreement, Jefferies will use commercially reasonable efforts, to sell ADSs by any method that is deemed to be an “at-the-market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”), including without limitation sales made through The Nasdaq Global Market or on any other existing trading market for the ADSs, or by any other method permitted by law. The Company has no obligation to sell any ADSs. The Company will pay Jefferies a commission of up to 3.0% of the gross sales proceeds of any ADSs sold through Jefferies under the Sales Agreement. The Company has also provided Jefferies with customary indemnification and contribution rights. The Sales Agreement contains customary representations and warranties and conditions to the placements of ADSs pursuant thereto. The Sales Agreement may be terminated by the Company or Jefferies upon written notice to the other party in accordance with the terms of the Sales Agreement. The offering of ADSs pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement in accordance with its terms.

    The ADSs will be issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-295992), including the Sales Agreement prospectus contained therein, filed with the Securities and Exchange Commission (the “SEC”) on May 18, 2026 (the “Registration Statement”), once the Registration Statement is declared effective by the SEC. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any ADSs under the Sales Agreement nor shall there be any offer, solicitation or sale of such ADSs in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

    Cooley (UK) LLP, counsel to the Company, has issued a legal opinion relating to the validity of the ADSs. A copy of such legal opinion, including the consent included therein, is filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    The foregoing description of the material terms of the Sales Agreement is qualified in its entirety by reference to the full text of the Sales Agreement, which is attached as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    Item 1.02 Termination of a Material Definitive Agreement.

    The information set forth above in Item 1.01 with respect to the termination of the Prior Sales Agreement is hereby incorporated by reference into this Item 1.02.

    Item 8.01. Other Events.

    The Company is updating its prior disclosures to reflect that, following further tax analysis, it believes that it should not have been classified as a passive foreign investment company (“PFIC”) for its taxable year ended December 31, 2025. Accordingly, the following risk factor is provided to supplement the Company’s risk factors previously disclosed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

     


     

    If we are a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. Holders.

    Under the Internal Revenue Code of 1986, as amended, or the Code, we will be a PFIC for any taxable year in which (i) 75% or more of our gross income consists of passive income, or (ii) 50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, passive income (including cash). For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets and received directly its proportionate share of the income of such other corporation.

    Although we believed that we may have been a PFIC for our taxable year ended December 31, 2025, we have performed further tax analysis and currently believe that, based on the nature of our activities and the composition of our income and assets, we were not classified as a PFIC for our taxable year ended December 31, 2025. However, no assurances regarding our PFIC status can be provided for any past, current or future taxable year. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis and the applicable law is subject to varying interpretation. In particular, the characterization of our assets as active or passive may depend in part on our current and intended future business plans, which are subject to change. In addition, the total value of our assets for PFIC testing purposes may be determined in part by reference to the market price of our ordinary shares or ADSs from time to time, which may fluctuate considerably. Under the income test, our status as a PFIC depends on the composition of our income which will depend on a variety of factors that are subject to uncertainty, including the characterization of certain intercompany payments and payments from tax authorities, transactions we enter into in the future and our corporate structure. Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the IRS would not successfully challenge our position. Accordingly, our U.S. counsel expresses no opinion with respect to our PFIC status for any prior, current or future taxable year.

    For each year we are treated as a PFIC with respect to U.S. Holders (as defined below), U.S. Holders will be subject to adverse U.S. federal income tax consequences, such as ineligibility for any preferential tax rates for individuals on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements under U.S. federal income tax laws and regulations, unless such U.S. Holder makes a “qualified electing fund” election, or QEF Election, with respect to all taxable years during such U.S. Holder’s holding period in which we are a PFIC, or our ordinary shares constitute “marketable stock” and such U.S. Holder makes a mark-to-market election. However, a U.S. Holder can only make a QEF Election with respect to ordinary shares or ADSs in a PFIC if such company agrees to furnish such U.S. Holder with certain tax information annually. As we do not believe that we were a PFIC for the taxable year ended December 31, 2025, we do not currently expect to provide such information for such taxable year and may not provide such information in future taxable years, whether or not we are classified as a PFIC.

    Each U.S. Holder should consult its own tax advisors with respect to the potential adverse U.S. tax consequences to it if we are or were to become a PFIC and any elections that may be available to such U.S. Holder that relate to our status as a PFIC.

    A “U.S. Holder” is a holder who, for U.S. federal income tax purposes, is a beneficial owner of our ordinary shares or ADSs and is:

    •
    a citizen or individual resident of the United States;
    •
    a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia;
    •
    an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or
    •
    a trust that (a) is subject to the primary supervision of a U.S. court and the control of one or more “United States persons” (within the meaning of Section 7701(a)(30) of the Code) or (b) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes.

     


     

    Item 9.01 Financial Statements and Exhibits

    (d) Exhibits.

    Exhibit

    Number

    Description

    1.1

    Open Market Sale AgreementSM by and between the Registrant and Jefferies LLC, dated May 18, 2026 (incorporated by reference to Exhibit 1.2 to the Company’s Registration Statement on Form S-3 (File No. 333-295992), filed with the Securities and Exchange Commission on May 18, 2026)

    5.1

     

    Opinion of Cooley (UK) LLP (incorporated by reference to Exhibit 5.1 to the Company’s Registration Statement on Form S-3 (File No. 333-295992), filed with the Securities and Exchange Commission on May 18, 2026)

    23.1

     

    Consent of Cooley LLP (included in Exhibit 5.1)

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    Cautionary Note Regarding Forward-Looking Statements

     

    This Current Report on Form 8-K may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. These forward-looking statements include statements about the Company’s expectations as to PFIC classification for the taxable year ended December 31, 2025. These forward-looking statements are based on information currently available to the Company and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including the likelihood of cash exercise during the extended term and potential proceeds to be received by the Company. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company’s business are described in additional detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in subsequent filings with the SEC. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    SILENCE THERAPEUTICS PLC

    Date: May 18, 2026

    By:

     /s/ Iain Ross

    Name: Iain Ross

    Title: Interim Principal Executive Officer and Chairman of the Board of Directors

    (Principal Executive Officer)

     

     


    Get the next $SLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLN

    DatePrice TargetRatingAnalyst
    2/11/2025$6.00Sell
    Goldman
    12/2/2024Outperform
    BMO Capital Markets
    9/3/2024$40.00Buy
    Jefferies
    1/31/2024$67.00Outperform
    BMO Capital Markets
    5/8/2023$20.00Overweight
    Morgan Stanley
    12/9/2022$18.00Equal-Weight
    Morgan Stanley
    3/31/2022$33.00Buy
    Chardan Capital Markets
    More analyst ratings

    $SLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Griffiths Richard Ian

    4 - Silence Therapeutics plc (0001479615) (Issuer)

    2/13/26 6:02:01 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ede-Golightly James

    4 - Silence Therapeutics plc (0001479615) (Issuer)

    1/6/26 4:15:24 PM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP and Chief R&D Officer Romano Steven J.

    4 - Silence Therapeutics plc (0001479615) (Issuer)

    1/6/26 4:15:13 PM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Silence Therapeutics to Participate in Jefferies Global Healthcare Conference

    Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET. A live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference. About Silence Therapeutics Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered me

    5/27/26 8:00:00 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference

    Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 19, 2026 at 2:00 p.m. ET. The live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference. About Silence Therapeutics Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing

    5/12/26 8:00:00 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results

    Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for topline results in August 2026 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March 31, 2026, and provided an update on recent business achievements. "The Silence team continues to advance research supporting the broad potential of our mRNAi GOLD™ platform, and we remain well positioned as we approach a significant company milestone," said Iain Ross, Chairman and Interim Principal Executive Officer at Silence. "With

    5/7/26 8:00:00 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLN
    SEC Filings

    View All

    SEC Form EFFECT filed by Silence Therapeutics Plc

    EFFECT - Silence Therapeutics plc (0001479615) (Filer)

    5/28/26 12:15:16 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Silence Therapeutics Plc

    424B5 - Silence Therapeutics plc (0001479615) (Filer)

    5/27/26 4:53:59 PM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silence Therapeutics Plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Silence Therapeutics plc (0001479615) (Filer)

    5/18/26 5:00:15 PM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Silence Therapeutics with a new price target

    Goldman initiated coverage of Silence Therapeutics with a rating of Sell and set a new price target of $6.00

    2/11/25 7:12:20 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets reiterated coverage on Silence Therapeutics

    BMO Capital Markets reiterated coverage of Silence Therapeutics with a rating of Outperform

    12/2/24 10:09:42 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Silence Therapeutics with a new price target

    Jefferies initiated coverage of Silence Therapeutics with a rating of Buy and set a new price target of $40.00

    9/3/24 8:14:09 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLN
    Leadership Updates

    Live Leadership Updates

    View All

    Silence Therapeutics Announces Leadership Changes

    Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the Company's President, Chief Executive Officer and Board member since 2022, agreed by mutual consent to end his employment with the Company effective 14 December 2025. Iain Ross, Chairman of the Silence Board, will lead the Company with immediate effect on an interim basis. Additionally, James Ede Golightly, a former Silence Non-Executive Director, has been re-appointed to the Company's Board of Directors. An additional appointment of an US-based Board member is anticipated in due

    12/15/25 8:13:00 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silence Therapeutics Welcomes Tim McInerney to Board of Directors

    Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting ("AGM") in June 2025. "We are thrilled to welcome Tim to the Silence Board," said Iain Ross, Chairman of the Silence Board. "Tim is a seasoned executive and board memb

    5/6/25 7:45:00 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

    Silence Therapeutics plc (NASDAQ:SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence's Board of Directors (the "Board") since 2015, informed the Company that he will retire from the Board, effective May 1, 2024. Iain Ross, Silence's Chairman of the Board, commented, "Alistair has made significant contributions to the Board and the Company over the past nine years. During his time on the Board, the Company has transitioned into a global player focused on the developmen

    4/29/24 8:30:00 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLN
    Financials

    Live finance-specific insights

    View All

    Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

    The Company's cash guidance is now extended into 2027 Company to host conference call and webcast today at 8 a.m. EST / 1 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a business update. "2024 was marked by strong clinical execution and pipeline advancement, highlighting the broad potential of our mRNAi GOLD™ platform to silence disease causing genes," said Craig Tooman, President and CEO of Silence. "In 2025, we are prioritizing investment in programs targeting rare conditi

    2/27/25 7:30:00 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

    Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025. Management will host a conference call at 8:00 a.m. ET / 1:00 p.m. GMT that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the Company's website. Deta

    2/13/25 8:00:00 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

    Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc ("Silence" or the "Company"), (NASDAQ:SLN), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced positive results from the ongoing SANRECO Phase 1 repeat dose study of divesiran (SLN124), a siRNA (short interfering RNA) targeting TMPRSS6, in patients with polycythemia vera (PV). "With today's very exciting PV da

    6/27/24 7:30:00 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

    SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

    11/14/24 1:13:14 PM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

    SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

    11/14/24 9:44:01 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

    SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

    11/12/24 4:31:49 PM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care